Table 2 –
BMI and FEV1 in children with PS-CF at 6, 12, and 16 years of age
| Age 6 years (n=325) | Age 12 years (n=129) | Age 16 years (n=57) | |
|---|---|---|---|
| BMI percentile | 0.13 (0.07, 0.20) ‡ | 0.13 (0.045–0.22)† | 0.22 (0.074–0.37)† |
| Female sex | 2.24 (−0.90, 5.40) | 1.80 (−2.82, 6.41) | 0.68 (−6.28, 7.65) |
| Non-white race | −0.22 (−6.55, 6.10) | −2.30 (−13.58, 9.00) | 4.36 (−7.41, 16.13) |
| Hispanic/Latino Data missing1 |
0.71 (−4.00, 5.42) 9.15 (1.34, 16.95)* |
−1.44 (−8.47, 5.59) 6.66 (−10.34, 23.66) |
−1.02 (−10.76, 8.73) −25.82 (−53.30, 1.66) |
| Non-private insurance Data missing1 |
−0.90 (−4.36, 2.56) −0.05 (−5.26, 5.17) |
−1.31 (−6.16, 3.53) −5.94 (−19.01, 7.14) |
−4.54 (−12.16, 3.08) −6.84 (−13.37, 27.05) |
|
Pseudomonas sp. Data missing1 |
0.55 (−2.74, 3.85) 49.31 (17.30, 81.32)† |
2.46 (−2.48, 7.41) n/a |
−3.44 (−10.86, 4.00) n/a |
|
Burkholderia sp. Data missing1 |
7.51 (−20.50, 35.52) −51.49 (−79.13, −23.86)‡ |
−3.37 (−16.65, 9.91) n/a |
−6.53 (−33.54, 20.48) n/a |
| Tobramycin | −4.38 (−10.00, 1.23) | −1.46 (−7.94, 5.01) | 10.71 (−1.17, 22.58) |
| HTS Data missing1 |
2.81 (−0.86, 6.48) 4.26 (−1.68, 10.20) |
−2.18 (−6.90, 2.53) n/a |
−0.40 (−8.02, 7.23) n/a |
| DNase | −1.21 (−4.52, 2.10) | 0.66 (−4.70, 6.02) | −5.11 (−13.78, 3.56) |
Results from cross-sectional adjusted linear regression at each age. Shown are effect estimates (β coefficients) for FEV1pp, with 95% confidence intervals (95%CI) in parentheses.
*
P<0.05,
†
P<0.01,
‡
P<0.001.
1
Variables with >10% missing data were assigned a “missing” category. HTS: Hypertonic saline.